ICIs have no/limited activity in EGFR+ NSCLC, and almost all clinical trials exclude EGFR+/ALK+ patients, which may be because previous trials mainly enrolled these common mutations (accounting for at least 80% of EGFR mutations), which have lower TMB levels. Here, ALK is linked to non-small cell lung carcinoma.